-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ Zhang Feng Lianchuang Beam Company’s first IND application approved by the FDA for the treatment of sickle cell diseaseYimai Meng broke the news Click on the picture , Sign up for the conference on November 12, 2021/eMedClub News/--Recently, Reindeer Medical announced its self-developed autologous T cell injection CT120 targeting CD19 and CD22 for the treatment of relapsed/refractory B cells The first patient enrollment and apheresis for non-Hodgkin's lymphoma (B-NHL) phase I/II registration clinical trials have been completed
.
At the same time, clinical trials of CT120 for the treatment of relapsed/refractory acute B-lymphocytic leukemia (B-ALL) are also about to start
.
This is China's first fully human dual-target CAR-T therapy approved to enter the clinical stage, and it is also the company's second CAR-T product
.
CT120 is a fully human-derived chimeric antigen receptor T cell injection targeting CD19 and CD22.
The extracellular domain of the CAR molecule contains two fully human scFv sequences that specifically bind to CD19/CD22.
Tumor cells expressing CD19/CD22 can reduce the escape of tumor cells caused by the loss of target antigen
.
CT120 adopts a fully humanized design, so its immunogenicity is low, which can reduce the risk of anti-ADA and improve the long-term survival ability of CAR-T cells in vivo
.
"This clinical trial is expected to enable patients to benefit from new drugs one step ahead of time and reduce the economic burden
.
Compared with the existing single-target CAR-T therapy, CT120 is expected to further reduce the risk of tumor recurrence and prolong the survival of patients in the clinic.
.
"The main investigator of the study, Professor Zhou Jianfeng, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, said, "In exploratory clinical trials, CT120 has shown good safety and effectiveness
.
Our hospital will work with all partners to advance the trial and benefit more patients
.
"This clinical study is a Phase I/II, multi-center clinical study.
In Phase I, CT120 is mainly used to evaluate the safety and safety of CT120 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).
Tolerability, phase II is mainly to evaluate the effectiveness of CT120 in the treatment of patients with B-NHL
.
Lymphoma is divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), of which about 90% are NHL
.
About 85% of NHL are relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)
.
B-NHL can be divided into diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) ), follicular lymphoma (FL), small lymphocytic lymphoma (CLL) and other subtypes
.
Among them, DLBCL is an aggressive B-NHL, and up to 50% of advanced patients relapse after first-line treatment and are difficult Re-treatment
.
Moreover, for R/R DLBCL patients, the treatment options are limited and the effect after treatment is unpredictable
.
FL is a slow-growing (indolent) form of B-NHL, and most of its cases are diagnosed as late
.
Although late The median survival period of FL is 8 to 15 years, but current treatment options cannot be cured, and most patients will relapse within 5 years
.
In addition, in some cases, FL can be converted to DLBCL
.
In China, the five-year survival rate for NHL patients is only 37%
.
According to the Frost & Sullivan report, the number of new cases of non-Hodgkin's lymphoma (NHL) in China in 2020 is about 90,000, and the number of patients is about 500,000.
It is expected that it will exceed 600,000 by 2025
.
"We got the approval from the National Genetics Office for this project on October 13 this year, signed a research contract with Tongji Hospital on October 14, and held a project kick-off meeting on the 15th.
After screening, we entered the first group at the end of October.
subjects
.
"says CEO Dr.
Wen-medical reindeer," IIT studies have shown that not only make the CT120 relapse did not receive the treatment of CAR-T / refractory B-NHL, B-ALL subjects benefit, but also It can benefit subjects who have previously received non-human single-target CAR-T treatment and whose disease has progressed
.
"At present, in addition to CT120, Reindeer Medical has multiple pipelines in different stages of development, of which the most rapidly progressing The product CT103A (fully human BCMA chimeric antigen receptor autologous T cell injection) is in the late stage of clinical development
.
These two CAR-T cell therapies also showed positive data in early clinical studies
.
▲Reindeer medical research pipeline (picture source: Reindeer medical official website) At present, CAR-T cell therapy has played a significant response and clinical efficacy in a variety of B-cell malignancies.
We look forward to more research data in the future, which can give Patients bring more clinical benefits
.
Reference materials: 1.
Reindeer Biotechnology "Reindeer Medical Announces the Completion of the First Patient Enrollment and Apheresis in CT120 Phase I/II Registration Clinical Study" 2.
http://
.
At the same time, clinical trials of CT120 for the treatment of relapsed/refractory acute B-lymphocytic leukemia (B-ALL) are also about to start
.
This is China's first fully human dual-target CAR-T therapy approved to enter the clinical stage, and it is also the company's second CAR-T product
.
CT120 is a fully human-derived chimeric antigen receptor T cell injection targeting CD19 and CD22.
The extracellular domain of the CAR molecule contains two fully human scFv sequences that specifically bind to CD19/CD22.
Tumor cells expressing CD19/CD22 can reduce the escape of tumor cells caused by the loss of target antigen
.
CT120 adopts a fully humanized design, so its immunogenicity is low, which can reduce the risk of anti-ADA and improve the long-term survival ability of CAR-T cells in vivo
.
"This clinical trial is expected to enable patients to benefit from new drugs one step ahead of time and reduce the economic burden
.
Compared with the existing single-target CAR-T therapy, CT120 is expected to further reduce the risk of tumor recurrence and prolong the survival of patients in the clinic.
.
"The main investigator of the study, Professor Zhou Jianfeng, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, said, "In exploratory clinical trials, CT120 has shown good safety and effectiveness
.
Our hospital will work with all partners to advance the trial and benefit more patients
.
"This clinical study is a Phase I/II, multi-center clinical study.
In Phase I, CT120 is mainly used to evaluate the safety and safety of CT120 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).
Tolerability, phase II is mainly to evaluate the effectiveness of CT120 in the treatment of patients with B-NHL
.
Lymphoma is divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), of which about 90% are NHL
.
About 85% of NHL are relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)
.
B-NHL can be divided into diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) ), follicular lymphoma (FL), small lymphocytic lymphoma (CLL) and other subtypes
.
Among them, DLBCL is an aggressive B-NHL, and up to 50% of advanced patients relapse after first-line treatment and are difficult Re-treatment
.
Moreover, for R/R DLBCL patients, the treatment options are limited and the effect after treatment is unpredictable
.
FL is a slow-growing (indolent) form of B-NHL, and most of its cases are diagnosed as late
.
Although late The median survival period of FL is 8 to 15 years, but current treatment options cannot be cured, and most patients will relapse within 5 years
.
In addition, in some cases, FL can be converted to DLBCL
.
In China, the five-year survival rate for NHL patients is only 37%
.
According to the Frost & Sullivan report, the number of new cases of non-Hodgkin's lymphoma (NHL) in China in 2020 is about 90,000, and the number of patients is about 500,000.
It is expected that it will exceed 600,000 by 2025
.
"We got the approval from the National Genetics Office for this project on October 13 this year, signed a research contract with Tongji Hospital on October 14, and held a project kick-off meeting on the 15th.
After screening, we entered the first group at the end of October.
subjects
.
"says CEO Dr.
Wen-medical reindeer," IIT studies have shown that not only make the CT120 relapse did not receive the treatment of CAR-T / refractory B-NHL, B-ALL subjects benefit, but also It can benefit subjects who have previously received non-human single-target CAR-T treatment and whose disease has progressed
.
"At present, in addition to CT120, Reindeer Medical has multiple pipelines in different stages of development, of which the most rapidly progressing The product CT103A (fully human BCMA chimeric antigen receptor autologous T cell injection) is in the late stage of clinical development
.
These two CAR-T cell therapies also showed positive data in early clinical studies
.
▲Reindeer medical research pipeline (picture source: Reindeer medical official website) At present, CAR-T cell therapy has played a significant response and clinical efficacy in a variety of B-cell malignancies.
We look forward to more research data in the future, which can give Patients bring more clinical benefits
.
Reference materials: 1.
Reindeer Biotechnology "Reindeer Medical Announces the Completion of the First Patient Enrollment and Apheresis in CT120 Phase I/II Registration Clinical Study" 2.
http://
